Samsung BioLogics implements new perfusion tech to reduce production time

By Jun Ji-hye

Samsung BioLogics has implemented new perfusion technology that would reduce production time by up to 30 percent for its clients, the contract drug manufacturer said Monday.

The company said it has successfully performed N-1 perfusion with an alternating tangential flow (ATF) device to supply the 15,000-liter commercial production process at the firm's third plant, the world's largest, located in Songdo.

The utilization of the perfusion technology on a large scale for commercial applications would contribute to intensifying bioprocessing and boosting productivity, the company said.

The technology would also allow clients to choose from a more diversified portfolio of manufacturing options.

The ATF perfusion system at Samsung BioLogics enables contract manufacturing organizations to cultivate higher cell culture densities up to tenfold, whilst retaining high cell viabilities at the seed stage to enable inoculation of the production bioreactors at higher cell densities.

The system is also aimed at achieving peak cell densities within shorter culture durations to improve productivity and reduce production time.

With implementation of large-scale N-1 perfusion, clients can leverage yet another innovative offering to boost their clinical and commercial production capability in addition to the comprehensive array of biopharmaceutical development, manufacturing and testing services at Samsung BioLogics, it said.